PL EN

Aktualności

EMA: Guideline on the use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products

02.02.2012
This guideline addresses the influence of pharmacogenetics on drug pharmacokinetics, encompassing considerations and requirements for the design and conduct of investigations during drug ...

EMA: Concept paper on key aspects for the use of pharmacogenomic methodologies in the pharmacovigilance evaluation of medicinal products

26.01.2012
Currently, there is limited information on the utilisation of a genomic biomarker during follow up (post marketing) or on the effect of labelling with genomic information. Therefore, guidance is ...

EMA: Draft guideline on the risk-based approach according to Annex I, part IV of Directive 2001/83/EC applied to advanced-therapy medicinal products

26.01.2012
This guideline describes the intention of the risk-based approach and details its methodological application. The methodology is based on the identification of risks and associated risk factors of ...

EMA: Draft guideline on the approach to establish a pharmacological acceptable daily intake

26.01.2012
This guideline gives advice on when to establish a pharmacological acceptable daily intake and provides guidance on the pharmacological studies and endpoints to be addressed. ...

EMA: Draft guideline on active-substance-master-file procedure (revision 3)

26.01.2012
This guideline replaces guideline CPMP/QWP/227/02 Rev 2 (EMEA/CVMP/134/02 Rev.2). ...

EMA: Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man

26.01.2012
The use of progression-free survival (PFS) or disease-free survival (DFS) as endpoint in clinical efficacy trials presents several methodological issues which need to be addressed prospectively. ...

EMA: Guideline on similar biological medicinal products containing interferon beta

19.01.2012
This guideline lays down the non-clinical and clinical requirements for interferon beta (IFN-β) containing medicinal products claiming to be similar to another interferon beta already marketed. ...

EMA: Draft guideline on clinical investigation of medicinal products other than non-steroidal anti-inflammatory drugs for treatment of rheumatoid arthritis

19.01.2012
This guideline replaces the points to consider on the clinical investigation of medicinal products other than non-steroidal anti-inflammatory drugs in rheumatoid arthritis (CPMP/EWP/556/95 rev. 1) ...

EMA: Guideline on the evaluation of anticancer medicinal products in man

19.01.2012
The purpose of this guideline is to provide guidance on all stages of clinical drug development for the treatment of malignancies, including drug resistance modifiers or normal tissue protective ...

EMA: Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections

12.01.2012
Guidance on evaluation of medicinal products indicated for the treatment of bacterial infections(CPMP/EWP/558/95 Rev 2) has been adopted. It provides details of requirements for clinical studies ...

kapitał ludzki

fundusz społeczny

Narodowe Centrum Badań i Rozwoju

innowacyjna gospodarka

rozwój regionalny